Cancer proliferation can be prevented by common pain medicine, studies

Taking a normal over-the-counter pain reliever can help prevent some cancer from spreading.

This according to a new study by the University of Cambridge, which found that aspirin can reduce cancer metastatis (proliferation) by stimulating the immune systems of the participants.

The conclusions were published on 5 March in Nature Journal Nature.

Aspirin colorectal can be associated with low risk of cancer, new studies show

In the mouse model, scientists found that a certain protein called Arhgef1 suppresses T-cells, which are immune cells that, according to a press release, can indicate and attack individual cancer cells away from the original tumor.

The Arhgef1 was “switched on” when T cells were brought into contact with the thromeboxen A2 (TXA2), a chemical produced by platelets that helps in blood clots. Excessive heart attacks and strokes of TXA2 can increase the risk.

This is where aspirin arrives – it is already known to prevent TXA2 production and prevent clots, which is why it may be recommended to prevent heart events in some people.

“Aspirin, or other drugs that can target this passage, have the ability to be less expensive than antibody-based treatments.”

“This new research found that aspirin prevents cancer from reducing TXA2 and releasing T cells from suppression,” the press release states.

In mice with melanoma, people who were given aspirin contained frequent metastases of cancer compared to those who were not given medicines.

After a heart attack, daily aspirin can reduce the risk of future events, finds studies

“This was a ‘Eureka’ moment when we found that TXA2 was a molecular signal that activates this oppressive effect on T cells,” in the release, the first author of the Department of Pathology at Cambridge University, Dr. Zee Yang said.

“Earlier, we did not know about the implications of our conclusions in understanding aspirin’s anti-metastatic activity,” he said.

“Aspirin, or other drugs that can target this route have the ability to be less expensive than antibody-based treatments, and therefore more accessible at the globally.”

Previous studies have suggested that daily aspirin treatment is associated with a decrease in cancer spread in humans with disease and with a decrease in cancer mortality in patients without metastasis, senior researcher Dr. Rahul Roychodhuri, Professor of Cancer Immunology at the University of Cambridge, said.

In a randomly controlled trial, carrying 600 mg aspirin to aspirin for an average reduced the occurrence of cancer in the carrier of hereditary colorectal cancer.

This can cause painful side effects of normal cancer treatment

Medical director of Gastrointestinal Medical Oncology of Hope Orange County in California, MD, MD, Pashtun Kasi reiterated that previous research has added aspirin the use of aspirin with a low risk of cancer, especially gastrointestinal tract cancer.

“It is identified in many studies, which is with mixed results to reduce the risk of recurrence and improve results in patients with metastatic cancer,” told Fox News Digital.

“This new study further indicates that the aspirin and other inhibitors of this route can be used in new treatments to prevent cancer from metastasiating or spreading.”

potential risk

Senior researcher, Royachodhuri took care in implementing the findings.

While aspirin is low cost and widely available, its long -term use is not without “significant risks”, he said, especially including abdominal bleeding and hemorrhagic stroke in older individuals.

“This is why we insist that patients should not start taking aspirin for cancer prevention without specific medical advice from their doctor,” he said in a statement to Fox News Digital.

The doctor said, “Risk-gain calculation varies largely between individuals based on age, comoridity and concurrent drugs.” “Patients interested in aspirin therapy should discuss this with their oncologist or family businessmen, who can evaluate potential benefits against risks.”

Click here to get Fox News app

Qasi indicated the potential limits of the study, mainly that the research was conducted on the model of mice rather than humans.

He said, “The study did not even notice that some people who use aspirin regularly experience, such as bleeding or interaction with other drugs,” he said.

“However, it constructs on the growing body of evidence … and provides a mechanical insight to how this effect can be from an immune perspective.”

Qasi agreed that patients should talk to their doctor to discuss the benefits and health risks related to regular aspirin use.

Click here to sign up for our health newspaper

“In some cases, low-khurak aspirin or other anti-inflammatory drugs are already considered in clinical use, as well as in additional trials-for examples, for individuals born with lynch syndromes, who have a high trend for the development of colorectal, endometrial and other cancer,” he said.

Next step

Scientists are planning to do more research-through an ad-spirin clinical trial, which will recruit more than 10,000 patients with early stages in the UK and India with the early phase of breast, colorectal, gastroosophage and prostate cancer-to determine whether Aspirin can prevent or delay the recurrence of these cancer.

“Patients interested in aspirin therapy should discuss this with their oncologist or family businessmen, who can evaluate potential benefits against risks.”

“Our research suggests that aspirin can potentially be the most beneficial for patients with early stage cancer, who have been treated with therapeutic intentions, but may disturb the unstable micromatasis,” said Roychoduri.

“However, before specific recommendations and clinical verification is required.”

For more health articles, travel www.foxnews.com/health

Research received funds from Medical Research Council, Welcome Trust and European Research Council.

Ad-Aspirin clinical trial is funded by Cancer Research UK, National Institute for Health and Care Research, Medical Research Council and Tata Memorial Foundation of India.